IL240727B - Peptides and compositions for the treatment of vertebral damage - Google Patents

Peptides and compositions for the treatment of vertebral damage

Info

Publication number
IL240727B
IL240727B IL240727A IL24072715A IL240727B IL 240727 B IL240727 B IL 240727B IL 240727 A IL240727 A IL 240727A IL 24072715 A IL24072715 A IL 24072715A IL 240727 B IL240727 B IL 240727B
Authority
IL
Israel
Prior art keywords
peptides
compositions
treatment
joint damage
damage
Prior art date
Application number
IL240727A
Other languages
English (en)
Hebrew (he)
Other versions
IL240727A0 (en
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL240727A0 publication Critical patent/IL240727A0/en
Publication of IL240727B publication Critical patent/IL240727B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1891Angiogenesic factors; Angiogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5939,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/01Hydrolysed proteins; Derivatives thereof
    • A61K38/012Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/014Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1875Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/225Calcitonin gene related peptide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/515Angiogenesic factors; Angiogenin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655Chondrocytes; Cartilage
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/17Angiopoietin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
IL240727A 2013-03-08 2015-08-20 Peptides and compositions for the treatment of vertebral damage IL240727B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361775400P 2013-03-08 2013-03-08
US201461938123P 2014-02-10 2014-02-10
PCT/US2014/022102 WO2014138687A1 (en) 2013-03-08 2014-03-07 Peptides and compositions for treatment of joint damage

Publications (2)

Publication Number Publication Date
IL240727A0 IL240727A0 (en) 2015-10-29
IL240727B true IL240727B (en) 2019-12-31

Family

ID=50390286

Family Applications (1)

Application Number Title Priority Date Filing Date
IL240727A IL240727B (en) 2013-03-08 2015-08-20 Peptides and compositions for the treatment of vertebral damage

Country Status (38)

Country Link
US (4) US9649359B2 (enExample)
EP (2) EP3391900A1 (enExample)
JP (3) JP6567429B2 (enExample)
KR (1) KR102267341B1 (enExample)
CN (2) CN105025917B (enExample)
AP (1) AP2015008675A0 (enExample)
AU (3) AU2014225348B2 (enExample)
BR (2) BR112015021269B1 (enExample)
CA (1) CA2903448C (enExample)
CL (1) CL2015002443A1 (enExample)
CO (1) CO7461145A2 (enExample)
CR (2) CR20200290A (enExample)
CU (1) CU24301B1 (enExample)
CY (1) CY1120729T1 (enExample)
DK (1) DK2964250T3 (enExample)
EA (1) EA035158B1 (enExample)
EC (1) ECSP15042898A (enExample)
ES (1) ES2684349T3 (enExample)
HR (1) HRP20181269T1 (enExample)
HU (1) HUE038499T2 (enExample)
IL (1) IL240727B (enExample)
JO (1) JO3564B1 (enExample)
LT (1) LT2964250T (enExample)
MX (1) MX365157B (enExample)
MY (1) MY173172A (enExample)
NZ (1) NZ711037A (enExample)
PE (1) PE20151528A1 (enExample)
PH (1) PH12015501983B1 (enExample)
PL (1) PL2964250T3 (enExample)
PT (1) PT2964250T (enExample)
RS (1) RS57446B1 (enExample)
SG (1) SG11201506490TA (enExample)
SI (1) SI2964250T1 (enExample)
TN (1) TN2015000385A1 (enExample)
TW (1) TWI634124B (enExample)
UY (1) UY35368A (enExample)
WO (1) WO2014138687A1 (enExample)
ZA (1) ZA201505966B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20160507A1 (es) 2009-07-14 2016-05-20 Scripps Research Inst Diferenciacion de celulas madre mesenquimales
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
UY35368A (es) 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
KR102117501B1 (ko) 2016-10-24 2020-06-01 스미또모 가가꾸 가부시키가이샤 세퍼레이터 및 세퍼레이터를 포함하는 이차 전지
JP6991593B2 (ja) * 2016-11-09 2022-01-12 アイシーエム・カンパニー、リミテッド Nkx3.2断片及び活性成分としてNkx3.2断片を含む医薬組成物
IL266361B2 (en) * 2016-11-14 2024-02-01 Novartis Ag Methods and preparations for the treatment of cartilage damage and arthritis
CN108530619B (zh) * 2017-03-01 2020-12-08 北京大学第三医院 功能化氨基酸、制备方法及由其制得的功能化氨基酸水凝胶
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
CN112424207B (zh) 2018-07-25 2024-03-19 诺华股份有限公司 Nlrp3炎性小体抑制剂
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
WO2021001804A1 (en) * 2019-07-04 2021-01-07 Cadila Healthcare Limited Angptl3 based vaccine for the treatment of liver disease
KR102577697B1 (ko) * 2019-11-13 2023-09-14 주식회사 나이벡 염증 및 상처 치료용 펩타이드
JP7298496B2 (ja) 2020-01-31 2023-06-27 トヨタ自動車株式会社 車両
TW202306970A (zh) 2021-05-24 2023-02-16 瑞士商諾華公司 用於治療骨關節炎之方法
CN117355323A (zh) 2021-05-24 2024-01-05 诺华股份有限公司 用于治疗骨关节炎的方法
CN113683681B (zh) * 2021-09-15 2023-10-03 山西锦波生物医药股份有限公司 一种重组i型人源化胶原蛋白c1l3t及其制备方法和用途
CN113683678B (zh) * 2021-09-15 2023-11-24 山西锦波生物医药股份有限公司 一种重组i型人源化胶原蛋白c1l2t及其制备方法和用途
EP4430395A1 (en) 2021-11-10 2024-09-18 Novartis AG Methods for determining the biological activity of angptl polypeptides
CN114377202B (zh) * 2021-12-16 2023-01-24 方向前 适用于软骨再生的功能化自组装miRNA/多肽复合水凝胶及其制备方法
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
KR20240087877A (ko) * 2022-12-09 2024-06-20 (주)케어젠 연골 재생용 펩타이드 및 이의 용도
WO2025169047A1 (en) 2024-02-05 2025-08-14 Novartis Ag Improved production of angptl3 mimetics

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
US5462990A (en) 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US5288931A (en) 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
WO1999058660A1 (en) 1998-05-12 1999-11-18 Human Genome Sciences, Inc. 97 human secreted proteins
US6030831A (en) 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
AU3661199A (en) 1998-04-27 1999-11-16 Zymogenetics Inc. Novel polypeptide growth factors and materials and methods for making them
AU4643699A (en) 1998-06-24 2000-01-10 Compugen Ltd. Angiopoietin-like growth factor sequences
AU768694B2 (en) 1999-03-08 2004-01-08 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
EP1159441B8 (en) 1999-03-10 2008-10-29 Marie Curie Cancer Care Delivery of nucleic acids and proteins to cells
GB9912350D0 (en) 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
AU4011300A (en) 1999-07-20 2001-02-05 Genentech Inc. Compositions and methods for the treatment of immune related diseases
US20030013649A1 (en) 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20030120056A1 (en) 2000-10-16 2003-06-26 Audrey Goddard TIE ligand homologues
AU2437702A (en) 2000-10-16 2002-04-29 Genentech Inc Methods of treatment using wisp polypeptides
US20020130430A1 (en) 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
US20030027751A1 (en) 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
EP1490483B1 (en) 2001-04-19 2015-06-03 The Scripps Research Institute In vivo incorporation of unnatural amino acids
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
FI117667B (fi) 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
ES2429034T3 (es) 2001-11-16 2013-11-12 Genentech, Inc. Uso de antagonistas de ANGPTL3 para el tratamiento de enfermedades hepáticas
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US7141540B2 (en) 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
GEP20074193B (en) 2002-09-09 2007-09-10 Nektar Therapeutics Al Corp Water-soluble polymer alkanals
KR20050073559A (ko) 2002-10-16 2005-07-14 더 스크립스 리서치 인스티튜트 당단백질 합성
DK1578949T3 (da) 2002-10-16 2009-07-27 Scripps Research Inst Stedspecifik optagelse af keto-aminnosyrer hos proteiner
CN103289960B (zh) 2003-04-17 2017-04-26 斯克利普斯研究院 扩展真核生物遗传密码
DE602004011789T2 (de) 2003-07-07 2009-02-12 The Scripps Research Institute, La Jolla Zusammensetzungen der orthogonalen Lysyl-tRNA und Aminoacyl-tRNA Synthetase Paaren und ihre Verwendungen
WO2005007870A2 (en) 2003-07-07 2005-01-27 The Scripps Research Institute COMPOSITIONS OF ORTHOGONAL LEUCYL-tRNA AND AMINOACYL-tRNA SYNTHETASE PAIRS AND USES THEREOF
WO2005007624A2 (en) 2003-07-07 2005-01-27 The Scripps Research Institute Compositions of orthogonal glutamyl-trna and aminoacyl trna synthetase pairs and uses thereof
EP1794323B1 (en) 2004-09-21 2014-08-06 The Scripps Research Institute In vivo incorporation of alkynyl amino acids into proteins in eubacteria
AU2005330514B2 (en) 2004-10-27 2011-05-12 The Scripps Research Institute Orthogonal translation components for the in vivo incorporation of unnatural amino acids
US20110097330A1 (en) 2005-03-11 2011-04-28 Genentech, Inc. Novel Gene Disruptions, Compostitions and Methods Relating Thereto
WO2006127809A2 (en) 2005-05-24 2006-11-30 Whitehead Institute For Biomedical Research Methods for expansion and analysis of cultured hematopoietic stem cells
CA2638763A1 (en) 2006-03-09 2007-09-13 The Scripps Research Institute System for the expression of orthogonal translation components in eubacterial host cells
AU2007328871B2 (en) 2006-12-06 2013-11-21 Seikagaku Corporation Pharmaceutical agent having long-lasting effect of treating arthritic disorders
CA2672049C (en) 2006-12-08 2016-05-10 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angptl3
EP2118150B1 (en) 2007-02-14 2015-09-23 Biocompatibles UK Limited Derivatisation of biological molecules
WO2008137641A2 (en) 2007-05-04 2008-11-13 Whitehead Institute For Biomedical Research Ex vivo expansion of human hematopoietic stem cells
PE20160507A1 (es) * 2009-07-14 2016-05-20 Scripps Research Inst Diferenciacion de celulas madre mesenquimales
US9732143B2 (en) 2011-02-03 2017-08-15 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2014004465A1 (en) 2012-06-25 2014-01-03 The Brigham And Women's Hospital, Inc. Targeted therapeutics
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
UY35368A (es) 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular

Also Published As

Publication number Publication date
TN2015000385A1 (en) 2017-01-03
MX365157B (es) 2019-05-24
AU2016203028C1 (en) 2017-06-01
AU2014225348A1 (en) 2015-09-10
JP6567429B2 (ja) 2019-08-28
AU2014225348B2 (en) 2016-03-31
US20170252407A1 (en) 2017-09-07
AU2016277608A1 (en) 2017-01-12
HRP20181269T1 (hr) 2018-10-19
HUE038499T2 (hu) 2018-10-29
US20160008433A1 (en) 2016-01-14
CN111808182A (zh) 2020-10-23
JP6918871B2 (ja) 2021-08-11
SG11201506490TA (en) 2015-09-29
CY1120729T1 (el) 2019-12-11
BR122016021558B1 (pt) 2023-03-28
JP2021178841A (ja) 2021-11-18
IL240727A0 (en) 2015-10-29
UY35368A (es) 2014-10-31
MX2015011963A (es) 2015-12-09
CL2015002443A1 (es) 2016-05-20
TWI634124B (zh) 2018-09-01
ECSP15042898A (es) 2019-03-29
ZA201505966B (en) 2017-03-29
US9649359B2 (en) 2017-05-16
LT2964250T (lt) 2018-07-25
JP2020015725A (ja) 2020-01-30
US11179442B2 (en) 2021-11-23
AP2015008675A0 (en) 2015-08-31
AU2016277608B2 (en) 2018-04-05
KR20150125712A (ko) 2015-11-09
US20200268849A1 (en) 2020-08-27
DK2964250T3 (da) 2018-08-06
CR20200290A (es) 2020-08-27
CN105025917B (zh) 2020-08-18
KR102267341B1 (ko) 2021-06-21
WO2014138687A1 (en) 2014-09-12
CU24301B1 (es) 2017-12-08
EP3391900A1 (en) 2018-10-24
PH12015501983A1 (en) 2016-01-11
US10328126B2 (en) 2019-06-25
EA035158B1 (ru) 2020-05-06
PT2964250T (pt) 2018-10-19
ES2684349T3 (es) 2018-10-02
BR112015021269B1 (pt) 2023-04-11
CO7461145A2 (es) 2015-11-30
PE20151528A1 (es) 2015-11-14
SI2964250T1 (sl) 2018-11-30
AU2016203028B2 (en) 2017-02-02
TW201444865A (zh) 2014-12-01
AU2016203028A1 (en) 2016-05-26
CR20150466A (es) 2015-10-27
BR122016021558A2 (pt) 2019-07-30
CA2903448C (en) 2021-03-23
EP2964250A1 (en) 2016-01-13
JO3564B1 (ar) 2020-07-05
MY173172A (en) 2020-01-02
PL2964250T3 (pl) 2018-10-31
RS57446B1 (sr) 2018-09-28
BR112015021269A2 (pt) 2017-10-10
CU20150097A7 (es) 2016-05-30
HK1214754A1 (en) 2016-08-05
EP2964250B1 (en) 2018-05-16
NZ711037A (en) 2018-07-27
CN105025917A (zh) 2015-11-04
US20220184182A1 (en) 2022-06-16
CA2903448A1 (en) 2014-09-12
PH12015501983B1 (en) 2020-09-25
JP2016510763A (ja) 2016-04-11
EA201591661A1 (ru) 2015-12-30

Similar Documents

Publication Publication Date Title
IL240727A0 (en) Peptides and compositions for the treatment of vertebral damage
IL286759A (en) Therapeutic methods and preparations
PT2968418T (pt) Preparações derivadas de materiais placentários e produção e utilização das mesmas
GB201320723D0 (en) Composition and methods of treatment
EP2958936A4 (en) METHOD AND COMPOSITIONS FOR TREATING CORI DISEASE
IL265876A (en) Preparations that include 15-ohepa and methods of using them
PT3021839T (pt) Composições para o tratamento da fibrose
SG11201508167PA (en) Therapeutic compositions and uses thereof
HUE057883T2 (hu) Peptid készítmények és felhasználási módszerek
IL244621A (en) Preparations for the treatment of hypertension and / or fibrosis
IL244622A0 (en) Preparations for the treatment of hypertension and/or fibrosis
SG11201507276UA (en) Improved methods of use for recombinant human secretoglobins
PL2968478T3 (pl) Kompozycje i sposoby do leczenia karboksyhemoglobinemii
ZA201509360B (en) Compositions and methods for treatment of stroke
GB201319255D0 (en) Therapeutic compositions and methods
GB201300628D0 (en) Compositions comprising 15-OHEPA and methods of using the same

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed